drugset / Trial / NCT06268886

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

NCT06268886

Phase 2 Active not recruiting 310 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.

Timeline

Start
2024-03-20
Primary completion
2027-03-18
Completion
2027-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986446 Monoclonal antibody